Oracle Delays OpenAI Data Centers to 2028 Amid Shortages
Oracle pushes back completion of massive OpenAI data centers by one year to 2028, citing labor and material shortages in $300B cloud computing deal.
NOTRELOAD AI
Rivian Surges as Self-Driving Tech Impresses Analysts
Rivian shares surge to nearly 2-year high as analysts praise custom autonomous driving chip and affordable AI features, positioning company as potential #2 EV player in North America.
ImmunityBio Shares Jump on European Bladder Cancer Treatment Recommendation
ImmunityBio stock climbed 8.5% after European regulators recommended approval for Anktiva, a bladder cancer treatment that helped over 70% of patients in clinical trials.
Guggenheim Upgrades Bristol Myers to Buy with $62 Target
Guggenheim raises Bristol Myers to Buy, citing low expectations, strong pipeline, and potential entry point for value-focused investors.
Arcus and Gilead Halt Cancer Trial After Treatment Fails to Extend Patient Survival
Arcus Biosciences discontinues Phase 3 STAR-221 cancer trial after independent review finds experimental treatment unlikely to improve survival for gastric and esophageal cancer patients.
Wells Fargo Upgrades Relay Therapeutics and Zymeworks Stocks
Wells Fargo upgrades Relay Therapeutics and Zymeworks, raising price targets and highlighting potential 2026 growth from clinical data and cancer treatment opportunities.